The regulatory and legal status of BPC-157 is that of an unapproved research compound in the United States and in most global jurisdictions, with no marketing authorization from any major regulatory agency for human therapeutic use
Interestingly, after 180 days, recovery occurred, and the number of large myelinated axons in the controls reached that in the BPC 157-treated rats, and this finding persisted through the end of the experiment (Fig
Your body, your mind, and your cells will thank you
[36] Mildronate has a similar structure to the natural substrate gamma-butyrobetaine, with a NH group replacing the CH 2 of gamma-butyrobetaine at the C-4 position
References Sikiric P, Seiwerth S, Rucman R, et al